FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.

This builds on Form's work with both companies. Form was one of the first telemedicine obesity care providers included on Lilly's digital healthcare platform, LillyDirect (TM), and was among the first ...

For a carbon-neutral bioeconomy, processes are needed that can efficiently capture CO2 and convert it into valuable products.

Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...

Fortress Biotech ( ($FBIO) ) has provided an announcement. On December 15, 2025, Fortress Biotech announced that the U.S. FDA accepted the ...

Fly this December and receive exclusive wildlife-themed amenity kits, highlighting endangered species with eco-friendly ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...

INmune Bio Inc. has announced the completion of the third and highest dose cohort in the Phase I portion of its clinical trial for the NK cell therapy INKmune™, which is aimed at treating men with ...

CHANGES — This photo, provided by Form Energy, shows the production floor of Form Factory 1 in Weirton. Form Energy confirmed a restructuring of its teams, which officials say will affect some of its ...